Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Camila Anna Gemperli"'
Autor:
Yanyun Gao, Philipp Zens, Min Su, Camila Anna Gemperli, Haitang Yang, Haibin Deng, Zhang Yang, Duo Xu, Sean R. R. Hall, Sabina Berezowska, Patrick Dorn, Ren-Wang Peng, Ralph Alexander Schmid, Wenxiang Wang, Thomas Michael Marti
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-22 (2021)
Abstract Background Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is below 10%, mainly due to
Externí odkaz:
https://doaj.org/article/77898471515947d0a1e1ce7aa86c96c0
Autor:
Zhang Yang, Wenxiang Wang, Duo Xu, Ralph A. Schmid, Patrick Dorn, Sean Hall, Yanyun Gao, Haitang Yang, Thomas M. Marti, Ren-Wang Peng, Sabina Berezowska, Haibin Deng, Camila Anna Gemperli, Min Su, Philipp Zens
Publikováno v:
Journal of experimental & clinical cancer research, vol. 40, no. 1, pp. 138
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-22 (2021)
Gao, Yanyun; Zens, Philipp; Su, Min; Gemperli, Camila Anna; Yang, Haitang; Deng, Haibin; Yang, Zhang; Xu, Duo; Hall, Sean R R; Berezowska, Sabina; Dorn, Patrick; Peng, Ren-Wang; Schmid, Ralph Alexander; Wang, Wenxiang; Marti, Thomas Michael (2021). Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR). Journal of experimental & clinical cancer research, 40(1), pp. 1-22. BioMed Central 10.1186/s13046-021-01938-2
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-22 (2021)
Gao, Yanyun; Zens, Philipp; Su, Min; Gemperli, Camila Anna; Yang, Haitang; Deng, Haibin; Yang, Zhang; Xu, Duo; Hall, Sean R R; Berezowska, Sabina; Dorn, Patrick; Peng, Ren-Wang; Schmid, Ralph Alexander; Wang, Wenxiang; Marti, Thomas Michael (2021). Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR). Journal of experimental & clinical cancer research, 40(1), pp. 1-22. BioMed Central 10.1186/s13046-021-01938-2
Background Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is below 10%, mainly due to resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a44caf4c75c7a449b199309c0a19c7cc
https://doi.org/10.1186/s13046-021-01938-2
https://doi.org/10.1186/s13046-021-01938-2